$PASG

Oppenheimer initiates Passage Bio stock with outperform rating

Oppenheimer has initiated coverage of Passage Bio Inc. (NASDAQ:PASG) with an outperform rating and a price target of $30.00, suggesting a significant upside of 385% from its current price. The firm believes the stock's 46% year-to-date decline is an overreaction to competitor program failures and regulatory concerns, presenting a buying opportunity. Oppenheimer highlighted key differentiators for Passage Bio's lead asset PBFT02 in frontotemporal dementia, projecting $1 billion in peak risk-adjusted sales by 2040.

Original reporting
Investing.com · Investing.com
Published Mar 31, 2026, 1:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 31, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oppenheimer initiates Passage Bio stock with outperform rating — source image
Decision brief

The 30-second read

$PASGBullishHigh
01

Why it matters

The analyst's positive outlook may catalyze a short-term rally, but underlying risks remain.

02

Market read

The coverage and target price could influence investor sentiment and trading volume in PASG.

03

What to watch

Potential delays in PBFT02 development or unforeseen regulatory challenges could limit upside.

Timing: Immediate, as the news is recent and impacts short-term sentiment.

Background

Passage Bio experienced a 46% decline year-to-date, attributed to sector-wide concerns and specific program setbacks.

Company-level read

Ticker impact

$PASGBullishHigh confidence
Context

High relevance due to recent analyst upgrade and significant upside potential.

Expected impact

Potential upward movement toward the $30 target, representing approximately 385% upside from current levels.

Evidence & confidence

The analyst's strong buy rating, high price target, and belief that recent declines are overreactions support a bullish outlook.

Market effects

Positive impact on the life sciences sector, especially biotech stocks with similar profiles.

Potential uplift in US biotech indices.

Limited, as Passage Bio is a US-based company with specific focus.

Counterpoint

The recent decline may reflect underlying issues not fully addressed by the analyst, such as regulatory hurdles or clinical trial setbacks.

Key entities

  • Passage Bio Inc.

    Biotech firm focusing on gene therapies for neurodegenerative diseases.

  • Oppenheimer

    Investment bank initiating coverage with a bullish rating.

Related articles

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.